Transcutaneous Tibial Nerve Stimulation for Spinal Cord Injury Neurogenic Bladder
Key facts
- Who runs it
- The University of Texas Health Science Center, Houston
- Where
- Houston and Washington D.C., United StatesSee the 2 sites
- Trial code
- Status
- Completed
- People taking part
- 111 people enrolled
- Started
- 8 Jun 2020
- Ended
- 11 Jun 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Variable-dose TTNS Protocol 5 x week
- Fixed-dose TTNS Protocol
- Variable-dose TTNS Protocol 2 x week
- Record updated
- 21 August 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- 18-75 years old
- Traumatic or non-traumatic SCI
- Admitted to inpatient rehabilitation within 6 weeks
- T9 level of injury and above who are at greatest risk of morbid NGB
- Regionally located to allow follow-up
- English or Spanish speaking
Who cannot take part
- History of central nervous system disorder (i.e. prior SCI, stroke, brain injury, Parkinson's disease, MS, etc.)
- History of genitourinary diagnoses (i.e. prostate hypertrophy, overactive bladder, cancer, etc.)
- History of peripheral neuropathy
- Potential for progressive SCI including neurodegenerative SCI, ALS, cancer myelopathy, Multiple sclerosis, transverse myelitis
- pre-SCI symptoms of peripheral neuropathy (numbness and/or tingling in feet, sharp/jabbing/burning pain in feet, sensitivity to touch, lack of coordination, muscle weakness, etc.)
- Pregnancy
- Known injury to the lumbosacral spinal cord or plexus, or pelvis with associated neuropathy
- concern for tibial nerve pathway injury
- absence of toe flexion or autonomic dysreflexia during electric stimulation test
Where in United States
- TIRR Memorial Hermann Research CenterHouston, United States
- MedStar National Rehabilitation HospitalWashington D.C., United States
About the trial
What the trial wants to find out
The purpose of this study is to determine if electric stimulation to the leg, called transcutaneous tibial nerve stimulation (TTNS), can improve bladder outcomes in acute spinal cord injury.
The 3 groups in the trial
- Variable-dose TTNS Protocol 5 x weekExisting treatment, for comparison
TTNS protocol: Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used. All participants will be instructed to use the device for 30 minutes, 5 days per week for the first 4 months post-sci.
- Fixed-dose TTNS protocolExisting treatment, for comparison
Fixed-dose protocol: Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes. Both variable-dose TTNS and fixed-dose TTNS protocol participants will be instructed to use the device for 30 minutes, 5 days per week.
- Variable-dose TTNS Protocol 2 x weekExisting treatment, for comparison
At the 4 month CMG, subjects initially randomized into the variable dose protocol of 2 x weekly will start doing so for the remainder of the study.
Results explained
A paper that names this trial, explained in plain words.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Urinary Biomarkers for Screening High-Risk Urodynamic Phenotypes in Early Spinal Cord Injury: A Pilot Study.Neurourology and urodynamics, 2026
- Record updated
- 21 August 2026